

1 P. 8
77

STA/STA

BRITISH MEDICAL JOURNAL

SATURDAY 5 APRIL 1975

LEADING ARTICLES

Lymphocyte Subpopulations in Chronic Inflammatory Diseases	page 1	Colour Disturbance
as a Symptom	page 2	Circadian Rhythms and Abortion
	page 3	page 3
Blunt Pancreatic Injury	page 4	Injudicious First-aid
	page 4	page 5
of Oil Related Industry	page 5	Medical Implications
	page 5	
	Treatment of Senile Macular Degeneration	page 6

PAPERS AND ORIGINALS

Long-term Study of Indomethacin and Alclofenac in Treatment of Rheumatoid Arthritis		
MANSEL AYLWARD, R. J. PARKER, F. HOLLY, J. MADDOCK, D. B. S. DAVIES		7
Deoxycytidylate Deaminase in Pregnancy	G. F. WILLIAMS, D. D. JONES.....	10
Falciparum Malaria Semi-resistant to Clindamycin	A. P. HALL, E. B. DOBERSTYN, A. NANAKORN, P. SONKOM.....	12
Falciparum Malaria Cured by Quinine Followed by Sulfadoxine-Pyrimethamine	A. P. HALL, E. B. DOBERSTYN, V. METTAPRAKONG, P. SONKOM.....	15
Origin of Urinary Fibrin Fibrinogen Degradation Products in Glomerulonephritis		
M. EKBERG, M. PANDOLFI.....		17
Methodichlorophen as Anti-tumour Drug	L. A. PRICE, J. H. GOLDIE, BRIDGET T. HILL	20
Roux Loop Drainage for Post-traumatic Biliary Cyst	J. K. TUCKER, W. G. EVERETT, J. M. SMITH.....	22

U. S. DEPT. OF AGRICULTURE
NATIONAL AGRICULTURAL LIBRARY
RECEIVED

U. S. DEPT. OF AGRICULTURE
NATIONAL AGRICULTURAL LIBRARY
RECEIVED

APR 1 1975

MEDICAL PRACTICE

Psychological Medicine: The Elderly Mind	H. M. HODKINSON.....	23
Surgery of Violence: VIII. Report on Injuries Sustained by Patients Treated at The Birmingham General Hospital Following the Recent Bomb Explosions	T. A. WATERWORTH, M. J. T. CARR.....	25
An Assessment of the Need for Follow-up of Patients with Pulmonary Tuberculosis Adequately Treated by Chemotherapy	BRITISH THORACIC AND TUBERCULOSIS ASSOCIATION JOINT TUBERCULOSIS COMMITTEE REPORT	28
Conversations with Consultants: Professional Satisfaction is Still Just Alive	FROM A SPECIAL CORRESPONDENT.....	29
Medical Examination of the Baby To Be Adopted	R. R. GORDON.....	31
Any Questions?	32
Personal View	E. H. DERRICK.....	33

PROCUREMENT SECTION CURRENT SERIAL RECORDS

CORRESPONDENCE—List of Contents	34
BOOK REVIEWS	43
OBITUARY NOTICES	44
NEWS AND NOTES	
Medicolegal—Defamation and Medical Journals	46
Medical News	46

SUPPLEMENT

General Medical Services Committee	48
Draft Model Contract for G.P.s	49
Review Body: Mrs. Castle's Letter to B.M.A. Secretary	50
B.M.A. Notices	50

CORRESPONDENCE

Antenatal Diagnosis of Spina Bifida R. Harris, M.D., and others; G. M. Addison, M.B., and others.....34	Measurement of Neonatal Growth D. P. Davies, M.R.C.P.....37	Heberden's Angina and Syncope Anginosa B. Livesley, M.R.C.P.....40
Alternatives to the Fluoridation of Water D. Jackson, D.D.S.....35	Misleading Drug Advertising A. J. Jouhar, M.B.....38	Kilo-what? D. B. Jelliffe, F.R.C.P., and E. F. Patrice Jelliffe, M.P.H.....40
Induction of Labour and Perinatal Mortality A. Singer, M.R.C.O.G., and I. D. Cooke, F.R.C.O.G.....35	Treatment of Sciatica G. Symonds, M.B.....38	Consultant Contract C. P. Lowther, F.R.C.P.ED.; R. S. Francis, F.R.C.P., and others; H. Miller, F.R.C.PATH...40
Dangers of Silent Gall Stones D. A. Jennings, B.M.....35	Overseas Doctors in the U.K. J. R. Mathers, F.R.C.PSYCH.....38	Salaries of Research Workers R. Schofield, PH.D., and others.....41
Reactions to Practolol W. A. Stubbs, M.R.C.S., and M. B. Ablett, M.B. 36	Distribution of Hospital Provision M. J. McCarthy, M.F.C.M.; D. P. Forster, M.R.C.PSYCH.....38	Fees for Insurance Reports J. P. Lask, M.R.C.G.P.....41
Neonatal Hyperthyroidism and Long-acting Thyroid Stimulator Protector J. A. Thomson, F.R.C.P.GLAS., and others.....36	Surgery in Rhodesia S. V. Humphries, F.R.C.S.....39	Polarization of Attitudes A. W. M. Gammon, M.B.....41
Treatment of Herpes Simplex with Co-trimoxazole Paula J. H. Gosling, M.B.....36	Specialists in Community Medicine D. G. H. Patey, M.F.C.M.....39	Points from Letters Laparoscopic Sterilization (A. D. Noble); Sea Urchin Spine Injury: Unorthodox Treatment (Lieutenant-Colonel C. M. J. O'Rourke); Special Diets in Hospital (E. A. Wilson); The Sleeping Baby (Louise F. W. Eickhoff); Routine Chest Radiographs in Hospital (P. O. Leggat); Gestation Age for Abortion (C. B. Goodhart); Financing General Practice (G. D. H. Shephard); Kilopascals (C. L. Tolhurst-Cleaver).....42
Tranquillizers Causing Aggression E. B. Gordon, M.R.C.PSYCH.....36	Geriatric Chairs K. Jones, F.R.C.P.I.....39	
Postoperative Management after Thyrectomy L. Loh, F.F.A.R.C.S., and J. M. Newsom Davis, F.R.C.P.; M. J. Lange, F.R.C.S. and T. H. Howells, F.F.A.R.C.S.....37	The Samaritans Doris M. Odum, F.R.C.PSYCH.....39	
	Treatment of Protein-losing Gastroenteropathy M. Kondo, M.D., and others.....40	
	Illness in the Clouds R. J. Fairhurst, M.B.....40	

Correspondents are urged to write briefly so that readers may be offered as wide a selection of letters as possible. So many are now being received that the omission of some is inevitable. Letters should be signed personally by all their authors.

Antenatal Diagnosis of Spina Bifida

SIR,—Further to your leading article (22 February, p. 414) we can add further reports of cases of spina bifida detected by amniotic α -fetoprotein (AFP) assay and, though serious closed lesions may be missed, the test is a good one.¹ We also agree that maternal serum AFP assay is currently able to detect at 16-20 weeks about one-third of cases of spina bifida.¹ You conclude that, in spite of being associated with at least 2% false positives, pregnant women with a risk of 1 in 20 of bearing a fetus with spina bifida can be identified, and general screening of all pregnancies by maternal serum AFP assay should now be considered. This is surprising since the assay technique is still subject to much inter-laboratory variation, it misses two-thirds of cases of spina bifida, and there are many practical and ethical problems still to be solved.

A minor revolution in obstetric practice would be necessary to obtain at 14-16 weeks serum from 800 000 pregnant women annually, especially in those areas where the majority do not book until later. Is it ethically justifiable to perform maternal serum assays on women who would never accept a termination of pregnancy, and should every woman undergoing this test be warned that amniocentesis would be indicated if the serum test is positive? Though unnecessary for the majority of anencephalics (detectable by ultrasound alone) 14 000 amniocenteses per year might be required, and it is doubtful whether sufficient equipment and trained technicians are available to allow preliminary ultrasound scan, without which the risks of amniocentesis may rise. Unwanted abortion

currently results from amniocentesis in approximately 1-2% of cases² and consequently each year 140-280 normal, wanted fetuses might be jeopardized. It is also generally agreed that chromosome studies should be carried out on specimens of amniotic fluid taken for AFP assay, but this is not always possible with the resources at present provided. It would be quite impossible on 14 000 amniotic fluid specimens a year and mongols would be missed.

Though the value to individual women of antenatal diagnosis is undisputed,³ population screening with a view to selective abortion is rather different and we must avoid the precipitate introduction of an unvalidated and costly screening programme based upon studies involving selected high-risk pregnancies which may not be representative of the general population of pregnant women. It is hoped that the enthusiasm created by your leading article will be channelled into well-controlled pilot studies of maternal serum assay and the establishment of regional teams providing specialized obstetric, radiological, genetic, and biochemical services directed to the improved antenatal detection of all birth defects.—We are, etc.,

R. HARRIS
R. F. JENNISON
A. J. BARSON

Department of Medical Genetics and Pathology,
St. Mary's Hospital, Manchester

¹ Harris, R., et al., *Lancet*, 1974, 1, 429.

² *British Medical Journal*, 1974, 4, 676.

³ Harris, H., *Prenatal Diagnosis and Selective Abortion*. London, Nuffield Provincial Hospitals Trust, 1974.

SIR,—Estimation of maternal serum α -fetoprotein (AFP) may prove to be of value in the clinical management of high-risk pregnancies, but the use of this test for antenatal mass screening for neural tube defects would represent such a fundamental change in obstetric practice that the implications of such a policy must be carefully evaluated before this procedure is introduced. We endorse the need for a scientific approach to the practical and ethical problems involved, but consider the rallying call in the last sentence of your leading article (22 February, p. 414) to be premature.

The need for careful investigation of the problems involved in measuring maternal serum AFP in order to define at the very least reliable estimates of test reproducibility, sensitivity, and specificity and the optimum time for the serum test is self-evident. In addition, public attitudes to the procedure need to be examined—for example, should patients be informed that blood is being taken for screening; should the benefits of compliance be stated; are there any hazards of compliance and if so what are they and should patients be informed?

Our concern that this screening procedure should be properly validated is further increased by the knowledge that a commercial kit for AFP radioimmunoassay is now available and doubtless others will soon be appearing on the market. Though these kits have a role to play in other branches of medicine, knowledge of their availability is certain to make it more difficult for obstetricians and chemical pathologists to resist the establishment of local screening programmes before their value has been properly established.

Hasty application of such tests will bring in its wake a great deal of unnecessary anguish (and possible risks to an otherwise normal pregnancy) for patients with false-